Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
258.2 CHF | +1.10% | +0.31% | -1.45% |
May. 22 | Roche: FDA designation for blood test | CF |
May. 22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
Sales 2024 * | 60.06B 65.71B | Sales 2025 * | 63.61B 69.6B | Capitalization | 187B 205B |
---|---|---|---|---|---|
Net income 2024 * | 13.41B 14.67B | Net income 2025 * | 14.87B 16.27B | EV / Sales 2024 * | 3.35 x |
Net Debt 2024 * | 13.78B 15.07B | Net Debt 2025 * | 7.77B 8.5B | EV / Sales 2025 * | 3.07 x |
P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
12.3
x | Employees | 103,605 |
Yield 2024 * |
4.19% | Yield 2025 * |
4.34% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +0.74% | ||
1 week | +0.16% | ||
Current month | +6.81% | ||
1 month | +2.80% | ||
3 months | +3.79% | ||
6 months | +2.23% | ||
Current year | -1.61% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.06% | 2 M€ | +9.19% | - | |
2.06% | 2 M€ | -.--% | - | |
0.84% | 17 M€ | 0.00% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 257.6 | +0.86% | 14 563 |
24-05-22 | 255.4 | -1.31% | 39,656 |
24-05-21 | 258.8 | +0.23% | 33,732 |
24-05-17 | 258.2 | +0.55% | 24,497 |
24-05-16 | 256.8 | +3.22% | 39,828 |
Delayed Quote Swiss Exchange, May 23, 2024 at 05:31 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+34.79% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.09% | 244B | |
+9.99% | 208B | |
+7.43% | 166B | |
+2.81% | 168B |
- Stock Market
- Equities
- ROG Stock
- RO Stock